SGLT2 Inhibitors and Cardiovascular Outcomes: Do They Differ or There is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study

被引：9

作者：

Kyriakos, Georgios ^{[1
]}

Quiles-Sanchez, Lourdes, V ^{[2
]}

Garmpi, Anna ^{[3
]}

Farmaki, Paraskevi ^{[4
]}

Kyre, Konstantina ^{[5
]}

Savvanis, Spyridon ^{[6
]}

Antoniou, Vasileios K. ^{[7
]}

Memi, Eleni ^{[8
]}

机构：

[1] Hosp Gen Univ Santa Lucia, Secc Endocrinol & Nutr, Cartagena, Spain

[2] Ctr Salud Jesus Marin, Murcia, Spain

[3] Natl & Kapodistrian Univ Athens, Laiko Gen Hosp, Med Sch, Internal Med Dept, Athens, Greece

[4] Natl & Kapodistrian Univ Athens, Aghia Sophia Childrens Hosp, Dept Pediat 1, Med Sch, Athens, Greece

[5] KAT Gen Hosp, Internal Med Dept, Athens, Greece

[6] Gen Hosp Athens Elpis, Dept Internal Med, Athens, Greece

[7] St Savvas Anticanc Hosp, Breast Surg Clin, Athens, Greece

[8] Ethnikon & Kapodistrian Univ Athens, Aretaieion Univ Hosp, Med Sch Athens, Unit Endocrinol Diabet Mellitus & Metab, Athens, Greece

来源：

CURRENT CARDIOLOGY REVIEWS | 2020年 / 16卷 / 04期

关键词：

SGLT2; inhibitors; T2DM; diabetes type 2 mellitus; EMPA-REG OUTCOME trial; CVD-REAL study; class effect; cardiovascular events; GLUCOSE COTRANSPORTER-2 INHIBITORS; HEART-FAILURE; DIABETES-MELLITUS; LOWERING DRUGS; EMPAGLIFLOZIN; RISK; MORTALITY; CANAGLIFLOZIN; SAFETY; DEATH;

D O I：

10.2174/1573403X15666190730094215

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A new group of hypoglycemic drugs has been used to treat diabetes type 2. This group is active sodium glucose co-transporter (SGLT2) or SGLT2 inhibitors. It has been shown that besides the treatment of diabetes, this drug class is responsible for the mildness of the cardiovascular events shown in patients with diabetes type 2. However, there is an intriguing question regarding the range of SGLT2 inhibitors and if there is a difference between them or if there is a class effect among their results. EMPA-REG OUTCOME trial and the CVD-study are used to answer this question. Additional information from the DECLARE-TIMI 58 and Dapa-HF trials is studied.

引用

页码：258 / 265

页数：8

共 50 条

[41] Lower Risk of CV Events and Death Associated with Initiation of SGLT2 vs. DPP-4 Inhibitors-Analysis from the CVD-REAL 2 Study
Kohsaka, Shun
Lam, Carolyn S.
Kim, Dae Jung
Karasik, Avraham
Tangri, Navdeep
Goh, Su-Yen
Thuresson, Marcus
Chen, Hungta
Surmont, Filip
Hammar, Niklas
Fenici, Peter
Kosiborod, Mikhail
DIABETES, 2018, 67
[42] Effect of empagliflozin when added to insulin in patients with type 2 diabetes and high cardiovascular (CV) risk: results from EMPA-REG OUTCOME
Jurisic-Erzen, D.
Johansen, O.
George, J.
Mattheus, M.
Zinman, B.
Inzucchi, S.
DIABETOLOGIA, 2016, 59 : S349 - S349
[43] Empagliflozin and progression of chronic kidney disease in type 2 diabetes complicated by nephrotic-range proteinuria: insights from the EMPA-REG OUTCOME trial
Ruggenenti, P.
Inzucchi, S.
Zinman, B.
Hantel, S.
Koitka-Weber, A.
von Eynatten, M.
Wanner, C.
DIABETOLOGIA, 2018, 61 : S508 - S508
[44] Effect of Empagliflozin (EMPA) on Anthropometry and Markers of Visceral and Total Adiposity by Age, Sex, and Degree of Abdominal Obesity in Patients with Type 2 Diabetes (T2D) and Cardiovascular Disease (CVD): EMPA-REG OUTCOME
Neeland, Ian J.
Mcguire, Darren K.
Mattheus, Michaela
Woerle, Hans Juergen
Johansen, Odd Erik
Fitchett, David
DIABETES, 2017, 66 : A2 - A2
[45] The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease
Kaku, Kohei
Wanner, Christoph
Anker, Stefan D.
Pocock, Stuart
Yasui, Atsutaka
Mattheus, Michaela
Lund, Soren S.
DIABETES OBESITY & METABOLISM, 2022, 24 (04): : 662 - 674
[46] Comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors: SGLT2 inhibitors in the real world
MacIsaac, Richard J.
Ekinci, Elif I.
ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (23)
[47] Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease: Survival Estimates From the EMPA-REG OUTCOME Trial
Claggett, Brian
Lachin, John M.
Hantel, Stefan
Fitchett, David
Inzucchi, Silvio E.
Woerle, Hans J.
George, Jyothis T.
Zinman, Bernard
CIRCULATION, 2018, 138 (15) : 1599 - 1601
[48] Lower cardiovascular risk with SGLT-2 inhibitors vs other glucose-lowering drugs: real world data from Asia Pacific, North America, Europe and Middle East: the CVD-REAL study
Kosiborodl, M.
Lam, C. S. P.
Kohsaka, S.
Kim, D.
Karasik, A.
Goh, S. -Y.
Shaw, J.
Tangri, N.
Norhammar, A.
Franch-Nadal, J.
Thuresson, M.
Surmont, F.
Hammar, N.
Fenici, P.
DIABETOLOGIA, 2018, 61 : S309 - S309
[49] A real-world comparison of cardiovascular, medical and costs outcomes in new users of SGLT2 inhibitors versus GLP-1 agonists
Poonawalla, Insiya B.
Bowe, Andy T.
Tindal, Michael C.
Meah, Yunus A.
Schwab, Phil
DIABETES RESEARCH AND CLINICAL PRACTICE, 2021, 175
[50] Real-World Analysis of SGLT2 Inhibitors to Prevent Cardiovascular and Kidney Outcomes in Patients with CKD: A Population-Based Cohort Study
Toro, Luis
Valderrama, Josefa
Polanco, Diego
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):

← 1 2 3 4 5 →